136 related articles for article (PubMed ID: 38776649)
1. Antidote-controlled DNA aptamer modulates human factor IXa activity.
Fang L; Jin J; Zhang Z; Yu S; Tian C; Luo F; Long M; Zuo H; Lou S
Bioorg Chem; 2024 Jul; 148():107463. PubMed ID: 38776649
[TBL] [Abstract][Full Text] [Related]
2. A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity.
Bompiani KM; Monroe DM; Church FC; Sullenger BA
J Thromb Haemost; 2012 May; 10(5):870-80. PubMed ID: 22385910
[TBL] [Abstract][Full Text] [Related]
3. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
Dyke CK; Steinhubl SR; Kleiman NS; Cannon RO; Aberle LG; Lin M; Myles SK; Melloni C; Harrington RA; Alexander JH; Becker RC; Rusconi CP
Circulation; 2006 Dec; 114(23):2490-7. PubMed ID: 17101847
[TBL] [Abstract][Full Text] [Related]
4. RNA aptamers as reversible antagonists of coagulation factor IXa.
Rusconi CP; Scardino E; Layzer J; Pitoc GA; Ortel TL; Monroe D; Sullenger BA
Nature; 2002 Sep; 419(6902):90-4. PubMed ID: 12214238
[TBL] [Abstract][Full Text] [Related]
5. In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry.
Tanaka KA; Szlam F; Rusconi CP; Levy JH
Thromb Haemost; 2009 May; 101(5):827-33. PubMed ID: 19404534
[TBL] [Abstract][Full Text] [Related]
6. Antidote control of aptamer therapeutics: the road to a safer class of drug agents.
Bompiani KM; Woodruff RS; Becker RC; Nimjee SM; Sullenger BA
Curr Pharm Biotechnol; 2012 Aug; 13(10):1924-34. PubMed ID: 22352726
[TBL] [Abstract][Full Text] [Related]
7. Construction of a Bivalent Thrombin Binding Aptamer and Its Antidote with Improved Properties.
Hughes QW; Le BT; Gilmore G; Baker RI; Veedu RN
Molecules; 2017 Oct; 22(10):. PubMed ID: 29048375
[TBL] [Abstract][Full Text] [Related]
8. A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor.
Chan MY; Rusconi CP; Alexander JH; Tonkens RM; Harrington RA; Becker RC
J Thromb Haemost; 2008 May; 6(5):789-96. PubMed ID: 18284597
[TBL] [Abstract][Full Text] [Related]
9. Rapid Complexation of Aptamers by Their Specific Antidotes.
Stoll H; Steinle H; Wilhelm N; Hann L; Kunnakattu SJ; Narita M; Schlensak C; Wendel HP; Avci-Adali M
Molecules; 2017 Jun; 22(6):. PubMed ID: 28594360
[TBL] [Abstract][Full Text] [Related]
10. A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery.
Nimjee SM; Keys JR; Pitoc GA; Quick G; Rusconi CP; Sullenger BA
Mol Ther; 2006 Sep; 14(3):408-15. PubMed ID: 16765093
[TBL] [Abstract][Full Text] [Related]
11. Hi-Fi SELEX: A High-Fidelity Digital-PCR Based Therapeutic Aptamer Discovery Platform.
Ouellet E; Foley JH; Conway EM; Haynes C
Biotechnol Bioeng; 2015 Aug; 112(8):1506-22. PubMed ID: 25727321
[TBL] [Abstract][Full Text] [Related]
12. A potent anti-coagulant RNA aptamer inhibits blood coagulation by specifically blocking the extrinsic clotting pathway.
Gopinath SC; Shikamoto Y; Mizuno H; Kumar PK
Thromb Haemost; 2006 May; 95(5):767-71. PubMed ID: 16676065
[TBL] [Abstract][Full Text] [Related]
13. Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant.
Soule EE; Bompiani KM; Woodruff RS; Sullenger BA
Nucleic Acid Ther; 2016 Feb; 26(1):1-9. PubMed ID: 26584417
[TBL] [Abstract][Full Text] [Related]
14. The effect of surface contact activation and temperature on plasma coagulation with an RNA aptamer directed against factor IXa.
Krishnan A; Vogler EA; Sullenger BA; Becker RC
J Thromb Thrombolysis; 2013 Jan; 35(1):48-56. PubMed ID: 23054460
[TBL] [Abstract][Full Text] [Related]
15. Antidote-controlled antithrombotic therapy targeting factor IXa and von Willebrand factor.
Becker RC; Oney S; Becker KC; Sullenger B
Ann N Y Acad Sci; 2009 Sep; 1175():61-70. PubMed ID: 19796078
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulant characteristics of HD1-22, a bivalent aptamer that specifically inhibits thrombin and prothrombinase.
Müller J; Freitag D; Mayer G; Pötzsch B
J Thromb Haemost; 2008 Dec; 6(12):2105-12. PubMed ID: 18826387
[TBL] [Abstract][Full Text] [Related]
17. An anticoagulant with light-triggered antidote activity.
Heckel A; Buff MC; Raddatz MS; Müller J; Pötzsch B; Mayer G
Angew Chem Int Ed Engl; 2006 Oct; 45(40):6748-50. PubMed ID: 16983715
[No Abstract] [Full Text] [Related]
18. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.
Chan MY; Cohen MG; Dyke CK; Myles SK; Aberle LG; Lin M; Walder J; Steinhubl SR; Gilchrist IC; Kleiman NS; Vorchheimer DA; Chronos N; Melloni C; Alexander JH; Harrington RA; Tonkens RM; Becker RC; Rusconi CP
Circulation; 2008 Jun; 117(22):2865-74. PubMed ID: 18506005
[TBL] [Abstract][Full Text] [Related]
19. DNA-Nanoscaffold-Assisted Selection of Femtomolar Bivalent Human α-Thrombin Aptamers with Potent Anticoagulant Activity.
Zhou Y; Qi X; Liu Y; Zhang F; Yan H
Chembiochem; 2019 Oct; 20(19):2494-2503. PubMed ID: 31083763
[TBL] [Abstract][Full Text] [Related]
20. Anti-factor IXa Aptamer reduces propagation of thrombin generation in plasma anticoagulated with warfarin.
Szlam F; Luan D; Bolliger D; Szlam AD; Levy JH; Varner JD; Tanaka KA
Thromb Res; 2010 May; 125(5):432-7. PubMed ID: 20004955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
